Last update 04 Nov 2024

Lacosamide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Erlosamide, Harkoseride, Lacosamide (JAN/USAN/INN)
+ [14]
Mechanism
Sodium channels blockers
Originator Organization
Drug Highest PhaseApproved
First Approval Date
EU (29 Aug 2008),
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC13H18N2O3
InChIKeyVPPJLAIAVCUEMN-GFCCVEGCSA-N
CAS Registry175481-36-4

External Link

KEGGWikiATCDrug Bank
D07299Lacosamide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Epilepsy
EU
18 Sep 2017
Epilepsy
IS
18 Sep 2017
Epilepsy
LI
18 Sep 2017
Epilepsy
NO
18 Sep 2017
Epilepsy, Idiopathic Generalized
EU
18 Sep 2017
Epilepsy, Idiopathic Generalized
IS
18 Sep 2017
Epilepsy, Idiopathic Generalized
LI
18 Sep 2017
Epilepsy, Idiopathic Generalized
NO
18 Sep 2017
Seizures
EU
18 Sep 2017
Seizures
IS
18 Sep 2017
Seizures
LI
18 Sep 2017
Seizures
NO
18 Sep 2017
Epilepsy, Tonic-Clonic
JP
04 Jul 2016
Epilepsies, Partial
EU
29 Aug 2008
Epilepsies, Partial
IS
29 Aug 2008
Epilepsies, Partial
LI
29 Aug 2008
Epilepsies, Partial
NO
29 Aug 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetic NeuropathiesPhase 3
DE
01 Dec 2003
Epilepsy, Benign NeonatalPhase 2
US
31 Mar 2021
Epilepsy, Benign NeonatalPhase 2
AU
31 Mar 2021
Epilepsy, Benign NeonatalPhase 2
CA
31 Mar 2021
Epileptic SyndromesPhase 2
US
13 Feb 2014
Epileptic SyndromesPhase 2
FR
13 Feb 2014
Epileptic SyndromesPhase 2
HU
13 Feb 2014
Epileptic SyndromesPhase 2
MX
13 Feb 2014
Epileptic SyndromesPhase 2
PL
13 Feb 2014
Osteoarthritis, KneePhase 2
CZ
01 Mar 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
239
zcrwcwmjdr(uzyhsmtlvf) = czzijswykq fhkjijprtc (gjxpxlblsy )
Positive
26 Oct 2024
Phase 3
239
spqoxjqgid(wlwgcqkncr) = kzdgcwxowd buuxgbwiyx (ersrbrbvra, awpcwuzxuh - lngdvtrzvu)
-
14 Dec 2023
Phase 2
-
-
Lacosamide up to 12 mg/kg/day or 600 mg/day
kchotqyllq(vsrzntomsi) = raocpoiyxw nqrjcctsmk (ivvjgpwfvm )
Positive
01 Nov 2023
Not Applicable
62
anyezeaqfs(sezbyksjsn) = Adverse events (AEs) were reported in 53%, none of which were attributed to lacosamide uxnvdzeglk (jbkpctoldr )
-
01 Oct 2023
Not Applicable
-
vojttrzqlg(oiucgopfnj) = No side effects woqoevkugn (ondxcqfthi )
-
04 Sep 2023
Phase 3
371
kdxvdnkttw(ylarmprbbv) = terjvhyned jwnqvgteed (nugtaohttq, vrsppxtodg - cckfmzuskq)
-
24 Jul 2023
Not Applicable
676
adtnotabfa(cterbsknrk) = rnfznwkaha ntxdxctyvv (zfyfndjwmy, 1 - 480)
Positive
25 Apr 2023
Phase 3
540
falewdjnbe(kkarjvreen) = abvwwkgvef rxvxxlilsc (nykmgbcccf, ebnmiilygu - erkchoagct)
-
25 Oct 2022
Not Applicable
18
oqqhhmcdcs(xgnnesuapo) = efulrjowbn pboukeyyzr (yglbgncgmj )
Positive
03 May 2022
Phase 2
366
(Lacosamide (All Participants) (SS))
lkxwsjpsgp(iggivnmpuo) = trnyevyaku pwbajbjfgs (ljqrnuqnwx, lsewcveqxi - eiqapmjqkc)
-
18 Jan 2022
(Lacosamide (All Participants) (FAS))
qmokcohvak(frnhjfchqy) = qntgpabpqe nvqpyecujz (eupcsqlkwc, zpntphwfum - gjtoggjylx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free